Transport Characteristics of a Beta Sheet Breaker Peptide Across Excised Bovine Nasal Mucosa
暂无分享,去创建一个
[1] A. Bernkop‐Schnürch,et al. Thiomers in noninvasive polypeptide delivery: in vitro and in vivo characterization of a polycarbophil-cysteine/glutathione gel formulation for human growth hormone. , 2004, Journal of pharmaceutical sciences.
[2] H. Feldman,et al. Treatment of Alzheimer's disease; current status and new perspectives , 2003, The Lancet Neurology.
[3] S. M. Robinson,et al. Pharmacological Profiles of Peptide Drug Candidates for the Treatment of Alzheimer's Disease* , 2003, The Journal of Biological Chemistry.
[4] J. Karlawish,et al. Alzheimer Disease: Current Concepts and Emerging Diagnostic and Therapeutic Strategies , 2003, Annals of Internal Medicine.
[5] L. Illum. Nasal drug delivery--possibilities, problems and solutions. , 2003, Journal of controlled release : official journal of the Controlled Release Society.
[6] M. Citron,et al. Alzheimer's disease: treatments in discovery and development , 2002, Nature Neuroscience.
[7] H. Natsume,et al. Analysis of transient and reversible effects of poly-L-arginine on the in vivo nasal absorption of FITC-dextran in rats. , 2002, Journal of controlled release : official journal of the Controlled Release Society.
[8] C. Soto,et al. Beta‐sheet breaker strategy for the treatment of Alzheimer's disease , 2002 .
[9] Claudio Soto,et al. Reduction of amyloid load and cerebral damage in transgenic mouse model of Alzheimer's disease by treatment with a β‐sheet breaker peptide , 2002, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[10] A. Bernkop‐Schnürch,et al. The Role of Glutathione in the Permeation Enhancing Effect of Thiolated Polymers , 2002, Pharmaceutical Research.
[11] W. Rubas,et al. Validation of excised bovine nasal mucosa as in vitro model to study drug transport and metabolic pathways in nasal epithelium. , 2000, Journal of pharmaceutical sciences.
[12] H. Natsume,et al. Screening of cationic compounds as an absorption enhancer for nasal drug delivery. , 1999, International journal of pharmaceutics.
[13] C. Soto,et al. Plaque busters: strategies to inhibit amyloid formation in Alzheimer's disease. , 1999, Molecular medicine today.
[14] A. Bernkop‐Schnürch,et al. Polymers with Thiol Groups: A New Generation of Mucoadhesive Polymers? , 1999, Pharmaceutical Research.
[15] H. Merkle,et al. Permeation and Pathways of Human Calcitonin (hCT) Across Excised Bovine Nasal Mucosa , 1998, Peptides.
[16] Romeo,et al. Effects of physicochemical properties and other factors on systemic nasal drug delivery. , 1998, Advanced drug delivery reviews.
[17] Hussain,et al. Intranasal drug delivery. , 1998, Advanced drug delivery reviews.
[18] Romeo,et al. Optimization of systemic nasal drug delivery with pharmaceutical excipients. , 1998, Advanced drug delivery reviews.
[19] Peter,et al. In vitro cell models to study nasal mucosal permeability and metabolism. , 1998, Advanced drug delivery reviews.
[20] H. Merkle,et al. Transport and Metabolic Pathway of Thymocartin (TP4) in Excised Bovine Nasal Mucosa , 1996, The Journal of pharmacy and pharmacology.
[21] Lisbeth Illum,et al. Absorption Enhancers for Nasal Drug Delivery , 2003, Clinical pharmacokinetics.
[22] B. Permanne,et al. Are β-sheet breaker peptides dissolving the therapeutic problem of Alzheimer’s disease? , 2002 .